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Objective: To evaluate the effectiveness of prophylactic administration of nepafenac 0.1% 
in maintaining mydriasis and in preventing postoperative macular edema following cataract 
surgery.
Methods: This was a prospective, randomized, single-masked comparative study in 60 patients 
undergoing phacoemulsiﬁ  cation cataract surgery. Patients were randomized to either the nepaf-
enac or the control group. Nepafenac was administered 3 times daily 1 day before surgery and 
continued for 6 weeks. The control group received tobramycin-dexamethasone treatment only. 
Trans-operative mydriasis was measured before surgery, after nuclear emulsiﬁ  cation, following 
cortex aspiration, and at the conclusion of surgery. Macular optical coherence tomography 
determined central foveal thickness (FT) and total macular volume (TMV) before surgery and 
at 2 and 6 weeks after surgery. All patients received tobramycin-dexamethasone for 2 weeks 
after surgery.
Results: The difference in mean pupil size, at the end of surgery, between the control group 
(6.84 ± 0.93 mm) and the nepafenac group (7.91 ± 0.74 mm) was statistically signiﬁ  cant 
(p  0.001). There were no signiﬁ  cant differences in FT values between the two groups at any 
time point; however, TMV at 2 and at 6 weeks was statistically signiﬁ  cantly different (p  0.001), 
with higher TMV in the control group.
Conclusion: Prophylactic use of nepafenac was effective in reducing macular edema after 
cataract surgery and in maintaining trans-operative mydriasis.
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Introduction
Phacoemulsiﬁ  cation with intraocular lens (IOL) implantation is currently the surgical 
procedure of choice for cataract surgery because it offers the best visual results.1–3 
However, despite the advances in surgical techniques (smaller clear corneal incision, 
and new ultrasound modalities) and improvements in IOL characteristics (acrylic 
hydrophobic materials), complications related to postoperative inﬂ  ammation persist 
and interfere with achieving optimal visual results.4
Eye trauma caused during surgery triggers the inﬂ  ammatory cascade, releasing a 
great number of mediators after the inﬂ  ammatory cells lyse, such as cyclooxygenase-1 
(COX-1) and COX-2 enzymes and prostaglandins (PGs). Some of the principal ocular 
signs and symptoms in which PGs are involved are inﬂ  ammation, pain, conjunctival 
hyperemia, miosis, changes in intraocular pressure (IOP), glaucoma, posterior 
synechiae, posterior capsular opacity, and cystoid macular edema (CME).5
Two important groups of drugs are used to control postoperative inﬂ  ammation 
following cataract surgery: non-steroidal anti-inﬂ  ammatory drugs (NSAIDs), which 
directly inhibit the COX enzymes, and topical corticosteroids, which act at the level 
of phospholipase A2, with the resultant inhibition of PG release6–13 (Figure 1). The 
simultaneous use of NSAIDs and corticosteroids provides a synergistic effect in con-
trolling intraocular inﬂ  ammation.14Clinical Ophthalmology 2009:3 220
Cervantes-Coste et al
Miosis induced by surgical trauma, primarily of the 
iris, is caused by the release of PGs. When PG release is 
inhibited with topical NSAIDs, adequate mydriasis is main-
tained during surgery, thereby decreasing trans-operative 
complications such as posterior capsule rupture.15 Currently, 
different non-invasive methods exist that prevent miosis 
during surgery; however, the use of preoperative topical 
NSAIDs, in combination with conventional topical myd-
riatics (anticholinergic and sympathomimetic), is widely 
practiced.13,16–20
In uncomplicated phacoemulsiﬁ  cation surgery, CME 
continues to be the most common cause of decreased visual 
acuity (VA) that appears between the 4th and 6th week after 
surgery. The development of CME is related to the disrup-
tion of the hemato-retinal and hemato-aqueous barriers and 
to the inﬂ  ammation induced by PGs and other inﬂ  ammatory 
mediators.21,22 The incidence of CME ranges from 1% to 6% 
to 20% to 30%.23,24 These percentages have been diminished 
with the use of topical NSAIDs.13,25,26
Nepafenac ophthalmic suspension 0.1% (Nevanac®, 
Alcon Laboratories, Inc., Fort Worth, TX, USA) is a new 
topical NSAID that is effective in the treatment of pain and 
postoperative inﬂ  ammation.27 Nepafenac is a prodrug, which 
is hydrolyzed in the intraocular tissues to amfenac, a potent 
inhibitor of COX-1 and COX-2 enzymes.28 The ocular bio-
availability and permeability of nepafenac, combined with its 
rapid bioactivation by ocular tissues, make it a target-speciﬁ  c 
NSAID for the inhibition of PG formation in the anterior 
and posterior segments of the eye.29 Its prodrug structure 
minimizes the risk of toxicity on the corneal surface and 
enhances its penetration to speciﬁ  c tissues.28,30,31
The purpose of this study was to evaluate the effective-
ness of the prophylactic administration of nepafenac 0.1%, in 
addition to standard antibiotic and corticosteroid treatment, 
in maintaining trans-operative mydriasis and in preventing 
postoperative macular edema during the ﬁ  rst 6 weeks fol-
lowing cataract surgery by phacoemulsiﬁ  cation. To the best 
of our knowledge, this is the ﬁ  rst study assessing the role of 
nepafenac in maintaining mydriasis during cataract surgery.
Patients and methods
This was a prospective, randomized, single-masked, single-
center, longitudinal, experimental and comparative study in 
patients undergoing phacoemulsiﬁ  cation cataract surgery 
at the Asociación Para Evitar la Ceguera en México, IAP 
Hospital “Dr Luis Sánchez Bulnes,” Anterior Segment 
Department. The Ethics and Research Committee of the 
institution approved the study and patients’ consent.
Sixty (60) patients who met the inclusion/exclusion 
criteria were included in the study. The inclusion criteria were 
adult patients 40 years of age or older, regardless of race or 
gender, who were diagnosed with senile and/or metabolic 
cataract (according to the Lens Opacities Classiﬁ  cation 
System LOCS III, with classiﬁ  cation NO and NC 2–3) and 
were scheduled for surgery by phacoemulsiﬁ  cation and IOL 
implantation inside the capsular bag, with a normal fundos-
copy exam (if observance was possible).
The exclusion criteria included any of the following 
conditions: pregnancy or breastfeeding; history of ocular 
inﬂ  ammatory or infectious eye disease; treatment for eye 
infection within 30 days prior to inclusion in the study; 
alterations on the eye surface (including dry eye); history of 
ocular surgery and/or trauma; and knowledge or suspicion of 
allergy or hypersensitivity to the preservatives, steroids, topi-
cal NSAIDs, or any other component of the study medication. 
Other exclusion criteria were use of eye medications, includ-
ing PG analogs; use of topical or systemic steroids within 
30 days prior to inclusion in the study; and use of topical or 
systemic NSAIDs within 14 days prior to inclusion in the 
study. Patients with non-controlled diabetes mellitus (DM), 
based on clinical history and blood glucose level (126 mg), 
proliferative diabetic retinopathy, and/or macular edema 
were excluded from the study. Preoperative mydriasis less 
than 6 mm prior to the study; synechiae; ocular alteration 
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Figure 1 Mechanism of action of non-steroidal anti-inﬂ  ammatory drugs (NSAIDs) and corticosteroids.Clinical Ophthalmology 2009:3 221
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preventing adequate mydriasis such as iris atrophy; macular 
alteration documented by optical coherence tomography 
(OCT), including macular edema of any etiology, macular 
holes, epiretinal membrane, macular degeneration related 
to age, and central serous chorioretinopathy; and the use of 
contact lens in the eye involved during the study were also 
considered exclusion criteria.
Study protocol
Preoperatively, all patients underwent a thorough ophthalmic 
examination and review of concurrent medications and 
medical history. The ophthalmic examination included 
best-corrected visual acuity (BCVA) (Snellen), slitlamp 
examination, IOP measurement by Goldmann applanation 
tonometry, and fundus examination. Macular OCT (Stratus 
OCT, Carl Zeiss Meditec, Dublin, CA, USA) was performed 
on all patients prior to surgery. The “Fast Macular Thickness 
Map” scan was used to determine the foveal thickness (FT, 
central 1 mm) in microns and total macular volume (TMV) 
in mm3, and to detect any macular alteration.
The combination of tropicamide 0.8% with phenylephrine 
5%, 1 drop every 15 minutes (2 doses) was used as a 
topical mydriatic in both treatment groups. Additionally, 
1 drop of nepafenac was administered every 15 minutes 
(4 doses) 1 hour prior to surgery in the nepafenac group. 
The identity of patients receiving preoperative mydriatic or 
preoperative mydriatic and nepafenac was concealed from 
the surgeons.
All patients underwent cataract surgery by phacoemulsiﬁ  -
cation and IOL implantation inside the capsular bag (Acrysof 
IQ, Toric or ReSTOR) under topical (1%) or retrobulbar 
(99%) anesthesia by 4 experienced surgeons.
Surgeons used the same standardized small-incision phaco-
emulsiﬁ  cation technique on all patients. Brieﬂ  y, 1.0 mm nasal 
and 2.8 mm temporal clear corneal incisions were made and a 
capsulorhexis 5.0 mm in diameter was created. A pre-chopped 
phacoemulsiﬁ  cation technique was used and foldable IOLs 
were implanted in the capsular bag. The corneal incisions were 
left sutureless. Phacoemulsiﬁ  cation parameters were estab-
lished prior to all surgeries and were the same in all patients. 
Cataract surgery was conducted using the Inﬁ  niti® Vision 
System with Ozil technology (Alcon Laboratories, Inc.). The 
preset parameters used were amplitude of 100%, balanced 
saline solution without epinephrine for irrigation, with the 
height of the bottle set at 110 cm, 38 ml/minute aspiration ﬂ  ow 
rate, 350 mmHg vacuum, and a dynamic rise of 1.
To ensure the standardization of illumination during 
pupillary measurement, all surgeons used the same microscope 
(Stativ S-8; Carl Zeiss Optronics, GmbH, Germany) and the 
illumination was kept constant in all cases. The horizontal and 
vertical diameters of the pupil were measured in millimeters 
with a compass under the microscope (directly on the eye) at 
the following stages: before surgery, after nuclear emulsiﬁ  -
cation, following cortex aspiration, and at the conclusion of 
surgery. The preset standard magniﬁ  cation of the operating 
microscope was ensured at each of the 4 time points.
All patients received topical antibiotic-corticosteroid 
(tobramycin-dexamethasone) treatment 4 times daily for 
10 days after surgery. The study group (nepafenac group) 
received 1 drop of nepafenac 3 times daily 1 day prior to sur-
gery and continued for 6 weeks afterward. The control group 
did not receive topical nepafenac. All patients were evaluated 
postoperatively at Day 1 and at Weeks 2 and 6 after surgery. 
At each visit, BCVA, slitlamp examination to measure cells 
and ﬂ  are in the aqueous humor (postoperative anterior cham-
ber inﬂ  ammation was graded according to the Standardization 
of Uveitis Nomenclature [SUN]),32 IOP measurements, and 
fundoscopy were evaluated. Macular OCT was repeated at 
2 and 6 weeks by a single observer in order to record FT, 
TMV, and any other macular alteration.
Statistical analysis
The data were compiled in Microsoft Excel and analyzed 
using SPSS (version 14, SPSS, Inc. Chicago, IL, USA). 
Data from patients in the nepafenac and control groups were 
described as mean values and proportions, and were com-
pared by using the ANOVA or Student’s t test. The Fisher 
exact test was used to associate the qualitative variables and 
to determine the relative risk. Statistical signiﬁ  cance was 
established at a p value of 0.05.
The demographic data included age, gender, and evalu-
ated eye, while the clinical data included the presence or 
absence of diabetes mellitus (without diabetic retinopathy, 
and the status of nonproliferative diabetic retinopathy), 
systemic arterial hypertension, and heart disease. The demo-
graphic data were compiled and compared between the two 
groups. The principal variables were mydriasis at the differ-
ent stages of surgery; and FT and TMV at baseline, 2 weeks, 
and 6 weeks after surgery.
Results
Sixty patients were included in the study; 30 patients were 
randomly selected for each group. Table 1 describes the 
demographic and clinical features of each group. There 
were no statistically signiﬁ  cant differences between the two 
groups. The average age of patients was 71.9 ± 9.7 years Clinical Ophthalmology 2009:3 222
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(range, 51 to 88); 22 patients (36.6%) were male. All patients 
completed the follow-up visits over a 6-week period. There 
were no serious treatment-related adverse events or toxicity 
related to the use of nepafenac 0.1%. Additionally, none of 
the patients presented with inﬂ  ammatory cells greater than 
1+ during the ﬁ  rst week of postoperative visits.
With respect to maintenance of mydriasis during cataract 
surgery (Table 2), the average preoperative horizontal pupillary 
diameter was comparable for both groups (8.44 mm and 
8.70 mm in the control and the nepafenac groups, respectively; 
p = 0.143). The difference in pupillary size at the conclusion 
of surgery was statistically signiﬁ  cantly (p < 0.001) different 
between the two groups (6.84 ± 0.93 mm and 7.91 ± 0.74 mm 
in the control and the nepafenac groups, respectively). The 
total reduction in pupil diameter from the beginning to the end 
of surgery was statistically signiﬁ  cantly (p  0.001) different 
between the control group (1.59 ± 0.94 mm) and the nepafenac 
group (0.78 ± 0.56 mm). This change of pupillary size at the 
conclusion of surgery can be also expressed as a percent total 
loss of mydriasis (failure to maintain mydriasis), which showed 
18.91% loss of mydriasis in the control group compared with 
9.03% loss in the nepafenac group (p  0.001). This indicates 
that prophylactic use of nepafenac is effective in maintaining 
mydriasis during cataract extraction and IOL implantation. 
Figure 2 shows the behavior of the horizontal pupillary size 
during the different stages of surgery. In the nepafenac group, 
the greatest failure in maintaining mydriasis occurred after 
phacoemulsiﬁ  cation of the lens nucleus, whereas in the control 
group, a gradual failure to maintain mydriasis was observed dur-
ing the entire surgical procedure. Of note, all patients had dark 
irises. Only 3 patients in the nepafenac group had a reduction 
in pupil size of 1.5 mm at the conclusion of surgery, while 
17 patients did so in the control group (p  0.001) (Table 3), 
demonstrating that the control group had a relative risk of 
decreasing pupil size by 1.5 mm during surgery 5.7 times 
greater than the nepafenac group.
The average FT by OCT obtained at the different visits is 
presented in Table 4. There were no statistically signiﬁ  cant 
differences between the control and nepafenac groups in FT 
(196.03 microns vs. 192.60 microns, p = 0.506) or TMV 
Table 1 Patients’ demographic and pre-operative systemic and ocular pathology
Parameter Group *p
Control (N = 30) Nepafenac (N = 30)
Age in years 0.561
 Mean  ± SD 71.2 ± 8.8 72.6 ± 10.5
  Range 51 to 85 52 to 88
Gender, N (%) 0.601
  Male 12 (40) 10 (33.3)
  Female 18 (60) 20  (66.6)
Eye, N (%) 0.838
  Right eye 14 (46.6) 15 (50)
  Left eye 16 (53.3) 15 (50)
Ocular and systemic pathology, N
 DM 7 5 0.572
  Without  DR 3 3 1.000
  With  DR 4 2 0.423
 Hypertension 7 10 0.477
 Heart  disease 4 3 0.662
*Student’s t test. 
Abbreviations: SD, standard deviation; DM, diabetes mellitus; DR, diabetic retinopathy.
Table 2 Mean horizontal diameter of the pupil during the different 
stages of cataract surgery
Surgery stages Group *p
Control 
(mm)
Nepafenac 
(mm)
Before surgery 8.44 ± 0.59 8.70 ± 0.75 0.143
After nuclear emulsiﬁ  cation 7.60 ± 0.84 8.17 ± 0.72 0.007
Following cortex aspiration 7.14 ± 0.87 8.13 ± 0.74 0.001
Conclusion of surgery 6.84 ± 0.93 7.91 ± 0.74 0.001
Total loss of mydriasisa 1.59 ± 0.94 0.78 ± 0.56 0.001
Percent total loss 18.91 9.03 0.001
*ANOVA; aDifference between pupil diameter before surgery and pupil diameter at 
the conclusion of surgery.Clinical Ophthalmology 2009:3 223
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(6.79 mm3 vs 6.65 mm3, p = 0.056). However, the TMV at 
2 weeks and at 6 weeks revealed statistically signiﬁ  cant 
differences (p  0.001) between both groups, with greater 
volume in the control group as compared with the nepafenac 
group (0.35 mm3 at 2 weeks and 0.38 mm3 at 6 weeks). FT 
at 2 weeks and at 6 weeks between both groups showed no 
statistically signiﬁ  cant differences (p = 0.111 and p = 0.062, 
respectively), due to the fact that the edema or accumulation 
of ﬂ  uids in the macular region was localized outside of 
the central foveal region. When analyzing the differences 
between the TMV at baseline and at 2 weeks and at 6 weeks 
in both groups (Table 5), the differences were statistically 
signiﬁ  cant (p  0.001) at both time periods, with greater TMV 
in the control group than in the nepafenac group.
Additionally, these variables were analyzed in associa-
tion with DM, and it was evident that in both groups the 
measurements of the diabetic patients were greater than the 
measurements of the non-diabetic patients, without having 
statistically signiﬁ  cant differences (Table 6). None of the 
patients developed clinically signiﬁ  cant macular edema asso-
ciated with vision loss; however, patients in the nepafenac 
group demonstrated less ﬂ  uid accumulation in the macular 
region than those in the control group, suggesting a protective 
effect with respect to macular edema occurrence.
Discussion
Prostaglandins play an important role in the response 
to ocular trauma (including surgical trauma), causing 
inﬂ  ammation, pain, trans-operative miosis, increased IOP, 
and pseudophakic CME, among others.5 Nepafenac 0.1% 
is a new-generation NSAID prodrug, which is hydrolyzed 
in the intraocular tissues to amfenac, a potent inhibitor of 
COX-1 and COX-2 enzymes, and thus, an inhibitor of PG 
synthesis. It has also demonstrated superior penetration of the 
intraocular tissues with adequate concentrations in the poste-
rior segment to inhibit the synthesis of PGs.27,28,30,31 Multiple 
studies have demonstrated that NSAIDs are effective drugs 
for maintaining trans-operative mydriasis13,16–20 and in pre-
venting and treating pseudophakic CME.21–26
The current study demonstrated that topical nepafenac 0.1% 
is an inhibitor of miosis during cataract surgery. In comparison 
to the control group, the nepafenac group showed a consistent 
tendency towards greater pupillary diameter during the differ-
ent stages of surgery, a decrease in the latter occurring mainly 
during phacoemulsiﬁ  cation of the lens nucleus. In the control 
group, a gradual failure in maintaining mydriasis was observed 
during the entire surgical procedure. Intracameral epinephrine 
was not used in the irrigation solution in this study because 
it interferes with the actual antimiosis effect of the NSAIDs 
p < 0.001  p = 0.007  p < 0.001 
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Figure 2 Comparison of horizontal pupil size in the nepafenac and control groups during surgery. 
Table 3 Decrease in pupil diameter (failure to maintain mydriasis) 
at the end of surgery and its relative risk
Group *p
Control Nepafenac 
Loss of 1.5 mm, N (%) 17 (85) 3 (15) 0.001
Relative risk 5.7 0.18  
*Fisher’s Exact test.Clinical Ophthalmology 2009:3 224
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studied. Shaikh and colleagues analyzed the antimiosis effect 
of topical prednisolone compared with ﬂ  urbiprofen. There 
were no statistically signiﬁ  cant differences between the two 
drugs; however, ﬂ  urbiprofen produced greater mydriasis.20 It 
has been reported also that the preoperative use of ketorolac 
for 3 days is more effective in maintaining mydriasis than the 
regimen of 1 day and 1 hour preoperatively.13 In this study, 
nepafenac was administered 1 day preoperatively; however, 
whether administration 3 days prior to surgery would make 
any difference in the outcomes is something that should be 
evaluated in the future.
Optical coherence tomography is a diagnostic tool that 
objectively quantiﬁ  es CME by means of changes in the direct 
measurements in TMV. Therefore, the OCT TMV parameter 
behaves as an objective indicator of macular swelling that 
clearly elucidates the amount of postoperative inﬂ  amma-
tion.33 Compared to ﬂ  uorescein angiography, OCT is a non-
invasive procedure and is useful for evaluations requiring 
multiple measurements, such as those related to macular 
edema after cataract surgery. Ozdemir and colleagues 
reported on the detection of CME after cataract surgery, 
not  by clinical examination of ﬂ  uorescein angiography, 
but by OCT.34 OCT has a sensitivity of 96%, speciﬁ  city of 
100%, provides greater evaluation of the axial distribution 
of accumulated ﬂ  uids, and has greater reproducibility than 
angiography.
In the current study, the control group showed greater 
accumulation of ﬂ  uids in the macular region compared 
with the nepafenac group. Clinical macular edema was not 
seen in any of the patients. Statistical analysis showed that 
46 patients per arm (80% power) were needed to show a 
statistical difference in FT between the two groups. Because 
no differences were observed in FT between groups at 
any visit, the authors were able to demonstrate that the 
accumulation of liquid in the retina occurred outside the 
central millimeter of the macula, a fact reported previously 
by Lobo and collaborators. The authors reported that the 
leakage sites were localized in the vascular regions of the 
macula and that the edema subsequently reached the central 
region.35 Furthermore, in a review conducted by Almeida 
and coworkers, it was found that, despite the absence of 
clinically signiﬁ  cant macular edema, patients treated with 
ketorolac had a protective effect in comparison with the 
control group regarding TMV obtained by OCT at 1 week 
and at 1 month after cataract surgery. The authors reported 
that the accumulation of ﬂ  uid in the patients treated with 
ketorolac was less in the various evaluation periods than 
in the control group.33 In the current study, patients in the 
nepafenac group showed a statistically signiﬁ  cant difference 
(p  0.001) in TMV with respect to baseline at the 2-week 
and 6-week visits (0.03 mm3 and 0.04 mm3, respectively), 
whereas in the control group TMV increases were 0.24 mm3 
and 0.28 mm3, respectively. Furthermore, when correlating 
the results with the presence of DM, patients with DM did 
not have statistically signiﬁ  cant differences in TMV in com-
parison with the non-diabetic patients.
Wolf and colleagues conducted a study similar to this 
current trial, in which the control group (prednisolone) and 
the study group (prednisolone-nepafenac) were evaluated 
and compared with respect to the presence of pseudophakic 
Table 4 Average foveal thickness (FT) and total macular volume (TMV) in the control and nepafenac groups
Group *p
Parameters Time point Control Nepafenac
FT, microns ± SD Baseline 196.03 ± 18.32 192.60 ± 21.33 0.506
2 weeks 203.46 ± 19.40 195.30 ± 19.66 0.111
6 weeks 203.86 ± 17.98 194.43 ± 20.26 0.062
TMV, mm3 ± SD Baseline 6.79 ± 0.189 6.65 ± 0.354 0.056
2 weeks 7.03 ± 0.212 6.68 ± 0.446 0.001
6 weeks 7.07 ± 0.242 6.69 ± 0.436 0.001
*ANOVA; p value represents the difference between the control and the nepafenac groups.
Abbreviations: SD, standard deviation; FT, foveal thickness; TMV, total macular volume.
Table 5 Differences in total macular volume (TMV) from baseline 
2 and 6 weeks after surgery
Time point Group *p
Control (mm3 ± SD) Nepafenac (mm3 ± SD)
2 weeks 0.241 ± 0.115 0.031 ± 0.224 0.001
6 weeks 0.277 ± 0.243 0.038 ± 0.242 0.001
*ANOVA.
Abbreviations: TMV, total macular volume; SD, standard deviation.Clinical Ophthalmology 2009:3 225
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macular edema, with a follow-up period of 4 weeks. 
Five patients in the control group (n = 240) had visually 
signiﬁ  cant pseudophakic macular edema compared to zero 
patients in the study group.36 These results can be related 
to this study, though a greater sample would be required. 
Hariprasad and colleagues reported that nepafenac 0.1% 
was effective in treating CME and diabetic macular edema 
(DME) in the presence or absence of concomitant steroid 
therapy. Six patients with CME (3 acute CME and 3 chronic 
CME) and 1 patient with DME were treated with nepafenac 
0.1%. Not only did nepafenac 0.1% reduce the retinal thick-
ness in these patients, but it also restored visual acuity. It is 
important to note that nepafenac was able to resolve chronic 
CME, which had failed to respond to conventional steroid/
NSAID therapy. Moreover, nepafenac was able to improve 
DME, a condition that has historically been resistant to 
pharmacologic treatment.37 Callanan and Williams reported 
that in a retrospective chart review of 6 eyes of 5 patients, 
nepafenac was effective in reducing OCT-measured FT in 
patients with DME.38 In a 15 patient study, Warren and Fox 
reported signiﬁ  cant improvement in visual acuity and retinal 
thickness after 4 and 12 weeks of 4 times daily treatment 
with nepafenac 0.1% compared with baseline.39
Until now, the prophylactic use of nepafenac 0.1% for 
maintaining mydriasis during cataract surgery, as well as the 
behavior of postoperative macular thickness, has not been 
reported; however, in this study signiﬁ  cant results in these 
aspects were found. More studies with larger sample sizes 
comparing nepafenac with other NSAIDs are warranted.
Conclusions
The prophylactic use of nepafenac 0.1% was effective and 
safe in maintaining mydriasis during cataract surgery as well 
as in reducing postoperative macular edema. This is the ﬁ  rst 
clinical study evaluating the effect of nepafenac 0.1% on 
pupil size during cataract surgery.
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